Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine - PubMed (original) (raw)
Clinical Trial
. 2004 Nov;53(11):1617-23.
doi: 10.1136/gut.2003.037747.
P Fric, J Pokrotnieks, M Lukás, B Fixa, M Kascák, M A Kamm, J Weismueller, C Beglinger, M Stolte, C Wolff, J Schulze
Affiliations
- PMID: 15479682
- PMCID: PMC1774300
- DOI: 10.1136/gut.2003.037747
Clinical Trial
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
W Kruis et al. Gut. 2004 Nov.
Abstract
Background and aims: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis.
Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses.
Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917 group and 38/112 (33.9%) in the mesalazine group (significant equivalence p = 0.003). Subgroup analyses showed no differences between the treatment groups in terms of duration and localisation of disease or pretrial treatment. Safety profile and tolerability were very good for both groups and were not different.
Conclusions: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.
Figures
Figure 1
Number of patients in the study at the time of clinical visits and at the final examination.
Figure 2
Proportion of patients experiencing a relapse of ulcerative colitis in the Escherichia coli Nissle 1917 (EcN) and mesalazine groups.
Figure 3
Probability of remaining in remission in the Escherichia coli Nissle 1917 (EcN) and mesalazine groups.
Figure 4
Endoscopic index and histology at the start and end of the study in the Escherichia coli Nissle 1917 (EcN) and mesalazine groups.
Similar articles
- [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B, Liebregts T, Holtmann G. Adam B, et al. Z Gastroenterol. 2006 Mar;44(3):267-9. doi: 10.1055/s-2005-858972. Z Gastroenterol. 2006. PMID: 16514573 German. No abstract available. - Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Rembacken BJ, et al. Lancet. 1999 Aug 21;354(9179):635-9. doi: 10.1016/s0140-6736(98)06343-0. Lancet. 1999. PMID: 10466665 Clinical Trial. - Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Kruis W, et al. Aliment Pharmacol Ther. 1997 Oct;11(5):853-8. doi: 10.1046/j.1365-2036.1997.00225.x. Aliment Pharmacol Ther. 1997. PMID: 9354192 Clinical Trial. - Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review. - Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
Losurdo G, Iannone A, Contaldo A, Ierardi E, Di Leo A, Principi M. Losurdo G, et al. J Gastrointestin Liver Dis. 2015 Dec;24(4):499-505. doi: 10.15403/jgld.2014.1121.244.ecn. J Gastrointestin Liver Dis. 2015. PMID: 26697577 Review.
Cited by
- Escherichia coli Nissle 1917 Protects against Sepsis-Induced Intestinal Damage by Regulating the SCFA/GPRs Signaling Pathway.
Wang Y, Deng H, Xiao L, Pan Y. Wang Y, et al. Microorganisms. 2024 Aug 8;12(8):1622. doi: 10.3390/microorganisms12081622. Microorganisms. 2024. PMID: 39203464 Free PMC article. - Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis.
Movva R, Murtaza N, Giri R, Png CW, Davies J, Alabbas S, Oancea I, O'Cuiv P, Morrison M, Begun J, Florin TH. Movva R, et al. Gastro Hep Adv. 2022 Mar 30;1(3):359-374. doi: 10.1016/j.gastha.2021.12.008. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131681 Free PMC article. - Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases.
Weibel N, Curcio M, Schreiber A, Arriaga G, Mausy M, Mehdy J, Brüllmann L, Meyer A, Roth L, Flury T, Pecina V, Starlinger K, Dernič J, Jungfer K, Ackle F, Earp J, Hausmann M, Jinek M, Rogler G, Antunes Westmann C. Weibel N, et al. ACS Synth Biol. 2024 Aug 16;13(8):2376-2390. doi: 10.1021/acssynbio.4c00036. Epub 2024 Aug 8. ACS Synth Biol. 2024. PMID: 39115381 Free PMC article. - Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis.
Dimopoulou C, Guerra PR, Mortensen MS, Kristensen KA, Pedersen M, Bahl MI, Sommer MAO, Licht TR, Laursen MF. Dimopoulou C, et al. Sci Rep. 2024 Jul 30;14(1):17542. doi: 10.1038/s41598-024-68412-9. Sci Rep. 2024. PMID: 39080343 Free PMC article. - Diminished Immune Response and Elevated Abundance in Gut Microbe Dubosiella in Mouse Models of Chronic Colitis with GBP5 Deficiency.
Li Y, Wang W, Liu Y, Li S, Wang J, Hou L. Li Y, et al. Biomolecules. 2024 Jul 20;14(7):873. doi: 10.3390/biom14070873. Biomolecules. 2024. PMID: 39062588 Free PMC article.
References
- British Society of Gastroenterology. Clinical practice guidelines: inflammatory bowel disease. 1996. www.bsg.org.uk/clinical-prac/guidelines.htm.
- Stange EF, Riemann J, von Herbay A, et al. Diagnosis and therapy of ulcerative colitis—results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 2001;39:19–20. - PubMed
- Travis SP, Jewell DP. Salicylates for ulcerative colitis—their mode of action. Pharmacol Ther 1994;63:135–61. - PubMed
- Shanahan F . Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000;6:107–15. - PubMed
- D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical